<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR54022</article-id>
      <title-group>
        <article-title>Formulation of Diclofenac Sodium Niosomes as Oral Drug Delivery System</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>J.Al_Gawhari</surname>
            <given-names>Fatima</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2015-08-01">
        <month>08</month>
        <day>01</day>
        <year>2015</year>
      </pub-date>
      <volume>5</volume>
      <issue>4</issue>
      <abstract>
        <p>Diclofenac sodium (DF) niosomes was formulated by sonication method using various proportions of tween 40, span 40 and cholesterol. Each formulation (F1, F2 and F3) was evaluated for vesicle size, drug entrapment efficiency, release of drug, osmotic and rheological properties. F1 with high surfactant level 20 µmol % of each surfactant tween 40 and span 40 has high entrapment efficiency (90.1%), high retention for DF during storage at 4˚C, 304 nm vesicle size and 96% release for 12 hours. All formulations have shear thinning flow and membrane rigidity due to presence of cholesterol in their bilayer membrane. Hence, using niosomes as an oral drug delivery system for DF is feasible approach.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>DF</kwd>
        <kwd>entrapment efficacy</kwd>
        <kwd>niosomes</kwd>
        <kwd>Vesicle diameter and Diclofenac.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
